Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases.
In an announcement, the company said the site will feature both a factory and a warehouse, designed to be modular and adaptable to support various rare disease products, including treatments for haemophilia.
Construction has already begun, with completion expected in 2027.
Novo has grown to become one of the world's most valuable drug companies thanks to the soaraway success of its weight loss and diabetes jabs Wegovy and Ozempic.